Skip to main content
. Author manuscript; available in PMC: 2013 Aug 7.
Published in final edited form as: Liver Int. 2010 Aug 25;31(3):330–339. doi: 10.1111/j.1478-3231.2010.02332.x

Figure 3.

Figure 3

Figure 3

a. Biochemical and virologic outcome of four representative reactivation cases.

R-ICE= Rituximab+ ifosfamide, carboplatin, etoposide; R-EPOCH=Rituximab + etoposide, prednisone, vincristine, cyclophosphamide, hydroxydaunorubicin; R-CHOP=Rituximab + cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone ; ALT= alanine aminotransferase; LAM= Lamivudine; TNF=Tenofovir; DNA= Viral Load (HBV DNA). Arrows = Indicate the time when the cycle of chemotherapy was administrated.

b. Biochemical and virologic outcome of two cases without reactivation that received antiviral prophylaxis.

R-CHOP =Rituximab + cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone ; ALT= alanine aminotransferase; LAM= Lamivudine; TNF=Tenofovir; DNA= Viral Load (HBV DNA). Arrows = Indicate the time when the cycle of chemotherapy was administrated.